A global leader in innovative solutions for the discovery, development, and manufacture of novel nanoparticle medicines.



Click to Watch:

Time: 13:00-15:00 GMT+1/ 8:00 AM EST /5:00 AM PST

Advances in mRNA Vaccine Therapies in the Fields of Cancer Immunotherapy and Infectious Diseases


Hear from Dr. Justin Richner and Dr Yvonne Perrie, leading experts on mRNA Vaccine Therapies in the fields of Cancer Immunotherapy and Infectious Diseases. 


Dr. Richner's research is on the emergence of Zika virus (ZIKV) infection has prompted a global effort to develop safe and effective vaccines. Recent technological advances have led to a number of promising vaccine platforms including antigen-coding mRNA vaccines encapsidated in a lipid nanoparticle (mRNA-LNP). Dr. Perrie's research is multi-disciplinary and is focused on the development of drug carrier systems to facilitate the delivery of drugs and vaccines, providing practical solutions for current healthcare problems.

Add to Calendar

Date: Wednesday, April 24, 2019

Time: 13:00-15:00 GMT+1/ 8:00 AM EST /5:00 AM PST


We hope to have you join!



Formulation Solutions Formulation Solutions Formulation Solutions
Thousands of compounds may be potential candidates for development as a medical treatment. Rapidly prepare low-volume nanoparticle formulations with the push of a button on the Spark™ or learn how Formulation Solutions can help with proof-of-concept nanoparticle formulations. Nanomedicine is playing a key role in pharmaceutical discovery, largely in the form of nanoparticle-based delivery systems for drugs.
After early testing, only a small number of compounds look promising and call for further study. In this stage, optimizing a wide range of nanomedicine formulations with the NanoAssemblr® Benchtop or the Blaze  depending on your volumes to allow you to gather the data on the effectiveness, required dosing and safety of a new therapy.
Develop nanoparticle drugs for clinical evaluation and to support clinical development for their commercialization. Scalable manufacturing is a significant challenge to making revolutionary medicine and Formulation Solutions is ready to assist you in your nanoparticle manufacturing process development. PNI provides a custom Clinical Solution for development and commercial supply.
Partners and Collaborators


  • "As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use." 
    - Don Enns, Vice President of Evonik Vancouver Laboratories
  • "We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens."
    - Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine (HIRM) at BIDMC
  • "Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr® GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines" 
    - Kristin DeFife, Ph.D., Vice President and Head of US Operations of Ajinomoto Bio-Pharma Services

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Our technology provides a seamless path forward to larger experimental studies, all the way to the clinic: low volume prototype formulations are easily scaled-up using larger instruments of the NanoAssemblr® family, which provides microfluidic mixing and manufacturing of nanoparticles.


Areas of Interest
Nanomedicines span many areas of interest. Explore resourceslike papers, application notes, scientific posters, webinars and more to see how nanotechnology is transforming medicine. 
of top pharmaceutical companies work with PNI

instruments are installed


biopharmaceutical labs use NanoAssemblr® instruments for nanomedicine drug development
Innovations that accelerate the drug development journey and enable the production of more sophisticated and powerful nanomedicines is our passion. We don’t do it alone, we pursue strategic collaborations that enable researchers to move quickly in the drug development process. Contact our Business Development Team.






PNI Feature in BioWorld


"As we bite off different problems and succeed on those, we can leverage those technologies," CEO Taylor explains. "We like to think that we're democratizing and lowering the barrier for people to get into these important technologies."

Evonik Collaboration


PNI announces a manufacturing collaboration agreement with Evonik for the tech transfer of the NanoAssemblr® system to Evonik Canada for late-stage clinical research.

License Agreement with Entos Pharmaceuticals


Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines.


Upcoming Events See All

April 29 -
May 03

The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

As the leading American conference focusing solely on gene and cell therapy, ASGCT’s annual meeting brings together over 2,500 professionals including scientists, physicians, and patient advocates.

April 30 -
May 03

CPhI North America

For nearly 30 years, CPhI has organized the world’s most influential pharmaceutical events. Several annual gatherings comprise our iconic worldwide portfolio, but it’s CPhI North America that has become the critical link in a global chain connecting motivated buyers w...

20 - 24

Tides: Oligonucleotides and Peptide Therapeutics

TIDES offers separate tracks covering the latest oligonucleotide and peptide development strategies from discovery, nonclinical, clinical and CMC to late-stage development and commercialization.

Resource Center

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More

Publication - Summary

February 07, 2019

Nano Research

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...

C. Zhang, X. Zhang, W. Zhao, C. Zeng, W. Li, B. Li, X. Luo, J. Li, J. Jiang, B. Deng, D.W. McComb, Y. Dong

Read More

Application Note

January 16, 2019

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Read More PDF

Publication - Summary

September 24, 2018

Nucleic Acid Therapeutics

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

R. Jain, JP. Frederick, EY. Huang, KE. Burke, DM. Mauger, EA. Andrianova, SJ. Farlow, S. Siddiqui, J. Pimentel, K. Cheun...

Read More


July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More PDF

Publication - Summary

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More
Resource Center

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.